Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 18, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on internal plan transactions rather than corporate financial performance.
Material Changes
Material changes reported relate to the notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan following a re-valuation on June 15, 2007, at a price of $52.75 per share:
- Increase: Mrs. C Bruck Slaoui received an increase of 3 notional ADRs.
- Decrease: Dr. R G Greig experienced a decrease of 1 notional ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction date: June 15, 2007.
- Transaction price: $52.75 per Ordinary Share ADR.
- Involved parties: Mrs. C Bruck Slaoui and Dr. R G Greig.
- Context: Re-valuation of the cash element within the US Retirement Savings Plan.